Literature DB >> 21556959

Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection.

Rick B Meeker1, Winona Poulton, Silva Markovic-Plese, Colin Hall, Kevin Robertson.   

Abstract

To begin to unravel the complexity of HIV-associated changes in the brain, broader, multifaceted analyses of cerebrospinal fluid (CSF) are needed that examine a wide range of proteins reflecting different functions. To provide the first broad profiles of protein changes in the CSF of HIV-infected patients, we used antibody arrays to measure 120 cytokines, chemokines, growth factors, and other proteins. CSF from HIV-infected patients with a range of cognitive deficits was compared to CSF from uninfected, cognitively normal patients to begin to identify protein changes associated with HIV infection and neurological disease progression. Uninfected patients showed relatively consistent patterns of protein expression. Highly expressed proteins in CSF included monocyte chemotactic protein-1, tissue inhibitors of metalloproteases, granulocyte colony-stimulating factor, adiponectin, soluble tumor necrosis factor receptor-1, urokinase-type plasminogen activator receptor, and insulin-like growth factor binding protein-2. Inflammatory and anti-inflammatory cytokines were expressed at low levels. HIV-infected patients showed increases in inflammatory proteins (interferon-gamma, tumor necrosis factor-alpha), anti-inflammatory proteins (IL-13), and chemokines but these correlated poorly with neurological status. The strongest correlation with increasing severity of neurological disease was a decline in growth factors, particularly, brain-derived neurotrophic factor and NT-3. These studies illustrate that HIV infection is associated with parallel changes in both inflammatory and neuroprotective proteins in the CSF. The inverse relationship between growth factors and neurological disease severity suggests that a loss of growth factor neuroprotection may contribute to the development of neural damage and may provide useful markers of disease progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21556959      PMCID: PMC3166824          DOI: 10.1007/s13365-011-0034-5

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  81 in total

Review 1.  Microglia and neuroprotection: implications for Alzheimer's disease.

Authors:  Wolfgang J Streit
Journal:  Brain Res Brain Res Rev       Date:  2005-01-15

2.  Variable progression of HIV-associated dementia.

Authors:  F H Bouwman; R L Skolasky; D Hes; O A Selnes; J D Glass; T E Nance-Sproson; W Royal; G J Dal Pan; J C McArthur
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

3.  Survival effects of BDNF and NT-3 on axotomized rubrospinal neurons depend on the temporal pattern of neurotrophin administration.

Authors:  L N Novikova; L N Novikov; J O Kellerth
Journal:  Eur J Neurosci       Date:  2000-02       Impact factor: 3.386

Review 4.  Brain-derived neurotrophic factor as a prototype neuroprotective factor against HIV-1-associated neuronal degeneration.

Authors:  R L Nosheny; I Mocchetti; A Bachis
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

5.  Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia.

Authors:  K Conant; J C McArthur; D E Griffin; L Sjulson; L M Wahl; D N Irani
Journal:  Ann Neurol       Date:  1999-09       Impact factor: 10.422

6.  BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

Authors:  Christine Stadelmann; Martin Kerschensteiner; Thomas Misgeld; Wolfgang Brück; Reinhard Hohlfeld; Hans Lassmann
Journal:  Brain       Date:  2002-01       Impact factor: 13.501

7.  Adiponectin acts in the brain to decrease body weight.

Authors:  Yong Qi; Nobuhiko Takahashi; Stanley M Hileman; Hiralben R Patel; Anders H Berg; Utpal B Pajvani; Philipp E Scherer; Rexford S Ahima
Journal:  Nat Med       Date:  2004-04-11       Impact factor: 53.440

8.  Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants.

Authors:  J Turchan; C B Pocernich; C Gairola; A Chauhan; G Schifitto; D A Butterfield; S Buch; O Narayan; A Sinai; J Geiger; J R Berger; H Elford; A Nath
Journal:  Neurology       Date:  2003-01-28       Impact factor: 9.910

9.  Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function.

Authors:  S Elkabes; E M DiCicco-Bloom; I B Black
Journal:  J Neurosci       Date:  1996-04-15       Impact factor: 6.167

10.  Cerebrospinal fluid and plasma concentrations of proinflammatory mediators in human immunodeficiency virus-infected children.

Authors:  Cynthia McCoig; María Mercedes Castrejón; Jesús Saavedra-Lozano; Elizabeth Castaño; Carmen Báez; E Randall Lanier; Xavier Sáez-Llorens; Octavio Ramilo
Journal:  Pediatr Infect Dis J       Date:  2004-02       Impact factor: 2.129

View more
  19 in total

1.  Cell trafficking through the choroid plexus.

Authors:  Rick B Meeker; Kimberly Williams; Deirdre A Killebrew; Lola C Hudson
Journal:  Cell Adh Migr       Date:  2012-08-20       Impact factor: 3.405

Review 2.  Glutamate metabolism and HIV-associated neurocognitive disorders.

Authors:  Fabián J Vázquez-Santiago; Richard J Noel; James T Porter; Vanessa Rivera-Amill
Journal:  J Neurovirol       Date:  2014-05-28       Impact factor: 2.643

3.  Opposing Effects of NGF and proNGF on HIV Induced Macrophage Activation.

Authors:  Kimberly S Williams; Deirdre A Killebrew; Gillian P Clary; Rick B Meeker
Journal:  J Neuroimmune Pharmacol       Date:  2015-09-29       Impact factor: 4.147

4.  Catechins protect neurons against mitochondrial toxins and HIV proteins via activation of the BDNF pathway.

Authors:  Samir Nath; Muznabanu Bachani; Deepti Harshavardhana; Joseph P Steiner
Journal:  J Neurovirol       Date:  2012-08-11       Impact factor: 2.643

5.  Specific protein profile in cerebrospinal fluid from HIV-1-positive cART-treated patients affected by neurological disorders.

Authors:  Valentina Zanin; Serena Delbue; Annalisa Marcuzzi; Eleonora Tavazzi; Rossella Del Savio; Sergio Crovella; Enrico Marchioni; Pasquale Ferrante; Manola Comar
Journal:  J Neurovirol       Date:  2012-05-12       Impact factor: 2.643

6.  Altered expression of fractalkine in HIV-1-infected astrocytes and consequences for the virus-related neurotoxicity.

Authors:  Vincent Sénécal; Corinne Barat; Marie-Thérèse Gagnon; François Vanasse; Mathieu Leboeuf; David Gosselin; Michel J Tremblay
Journal:  J Neurovirol       Date:  2021-03-01       Impact factor: 2.643

7.  Insulin-like growth factors and related proteins in plasma and cerebrospinal fluids of HIV-positive individuals.

Authors:  Hyeon-Sook Suh; Yungtai Lo; Namjong Choi; Scott Letendre; Sunhee C Lee
Journal:  J Neuroinflammation       Date:  2015-04-15       Impact factor: 8.322

8.  Monocytes-derived macrophages mediated stable expression of human brain-derived neurotrophic factor, a novel therapeutic strategy for neuroAIDS.

Authors:  Jing Tong; Shilpa Buch; Honghong Yao; Chengxiang Wu; Hsin-I Tong; Youwei Wang; Yuanan Lu
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

9.  Suppression of HIV-associated Macrophage Activation by a p75 Neurotrophin Receptor Ligand.

Authors:  Deirdre A Killebrew; Kimberly S Williams; Youmei Xie; Frank Longo; Rick B Meeker
Journal:  J Neuroimmune Pharmacol       Date:  2021-07-22       Impact factor: 7.285

10.  Evidence of the innate antiviral and neuroprotective properties of progranulin.

Authors:  Hyeon-Sook Suh; Yungtai Lo; Namjong Choi; Scott Letendre; Sunhee C Lee
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.